07:00 , Apr 14, 2008 |  BC Week In Review  |  Company News

AdnaGen management update

AdnaGen AG , Langenhagen, Germany   Business: Diagnostic, Cancer   Hired: Wolfram Rodatz as CEO, formerly general manager at Digilab BioVisioN GmbH  ...
07:00 , Jun 11, 2007 |  BC Week In Review  |  Company News

Digilab, GenWay Biotech deal

Digilab's Digilab BioVisioN GmbH subsidiary will provide services to the research market using GenWay's Seppro IgY technology, which removes high abundance proteins from human serum or plasma samples, detects biomarkers and identifies drug targets that...
08:00 , Jan 1, 2007 |  BC Week In Review  |  Company News

Digilab, Abbott deal

Digilab's Digilab BioVisioN GmbH subsidiary received undisclosed milestone and research payments from ABT under a 2005 agreement to discover tumor biomarkers using BioVisioN's Peptidomics Differential Peptide Display technology (see BioCentury, Sept. 19, 2005). BioVisioN identified...
07:00 , Aug 14, 2006 |  BC Week In Review  |  Company News

Digilab BioVisioN GmbH, Novartis deal

Digilab will use its Peptidomics peptide profiling and discovery technology to analyze the peptide content of biological samples supplied by NVS to discover biomarkers. Digilab will receive a research payment and is eligible for milestones...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Company News

Proteome Sciences board of directors update

Proteome Sciences plc (LSE:PRM), Cobham, U.K.   Business: Proteomics   Hired: Peter Schulz-Knappe as CSO and R&D director, formerly CSO of BioVisioN AG  ...
07:00 , Jul 24, 2006 |  BioCentury  |  Finance

Ebb & Flow

The $365 million in cash that Gilead (GILD) is paying for the 87% of Corus it did not already own is giving the private company a total imputed value of $420 million, almost certainly a...
08:00 , Mar 13, 2006 |  BC Week In Review  |  Company News

Digilab BioVisioN AG, Boehringer Ingelheim deal

Digilab will use its Peptidomics peptide profiling and discovery technology to analyze the peptide content of biological samples for Boehringer. Further terms were not disclosed. Digilab BioVisioN AG , Hanover, Germany   Boehringer Ingelheim GmbH...
08:00 , Mar 6, 2006 |  BC Week In Review  |  Company News

BioVisioN, Digilab deal

Digilab, a developer of molecular spectroscopy products, acquired BioVisioN for an undisclosed amount of cash. The deal includes BioVisioN's Peptidomics peptide profiling and discovery technology. BioVisioN AG , Hanover, Germany   Digilab LLC , Canton,...
07:00 , Sep 19, 2005 |  BC Week In Review  |  Company News

BioVisioN, Abbott deal

BioVisioN will use its peptide biomarker discovery technology to analyze biological samples provided by ABT for use in discovering tumor biomarkers. BioVisioN will receive research payments and is eligible for milestones and royalties. BioVisioN AG...
07:00 , May 30, 2005 |  BC Week In Review  |  Company News

BioVisioN, ImVisioN GmbH deal

ImVisioN acquired rights to BioVision's IP covering the MAT (Modular-Antigen-Transport) technology. ImVisioN also acquired exclusive rights to a patent application covering the recombinant expression of Fel d1 , a cat dander allergen. ImVisioN's IVN201 is...